Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Marco Bellone"'
Autor:
Vincenzo Baldo, Marco Bellone
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 23, Iss 1 (2022)
BACKGROUND: Vaccination is the most effective way to prevent influenza and its complications. The MF59-adjuvanted quadrivalent (aQIV) and the high-dose quadrivalent (QIV-HD) influenza vaccines have been specifically developed to protect subjects aged
Externí odkaz:
https://doaj.org/article/986eda4337d3408f986096870cb775ed
Autor:
Marco Bellone, Lorenzo Pradelli, Rita Tavarozzi, Marco Ladetto, Giuliana Nepoti, Emanuele Guardalben, Daniela Ghislieri
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 23, Iss 1 (2022)
OBJECTIVE: To assess time- and cost-savings in relation to active time of health care professional (HCP) and resource consumption of administering obinutuzumab as a short duration infusion (SDI) in patients in treatment for Follicular Lymphoma (FL).
Externí odkaz:
https://doaj.org/article/13425f1eed7c4f0c8e1de77af0c6da82
Autor:
Patrizia Berto, Marco Bellone, Alice Sabinot, Carmine Pinto, Massimo Martino, Daniele Generali, Pier Luigi Carriero, Maria Domenica Sanna
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 23, Iss 1 (2022)
INTRODUCTION: Current Italian guidelines recommend prophylaxis with granulocyte colony-stimulating factors (G-CSFs) to reduce the risk of chemotherapy-induced febrile neutropenia (FN). The availability of G-CSF biosimilars represents an opportunity f
Externí odkaz:
https://doaj.org/article/1f453d59d0d94bbcbc656b42c6afb5ce
Autor:
Stefan Schraag, Lorenzo Pradelli, Abdul Jabbar Omar Alsaleh, Marco Bellone, Gianni Ghetti, Tje Lin Chung, Martin Westphal, Sebastian Rehberg
Publikováno v:
BMC Anesthesiology, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background It is unclear if anaesthesia maintenance with propofol is advantageous or beneficial over inhalational agents. This study is intended to compare the effects of propofol vs. inhalational agents in maintaining general anaesthesia on
Externí odkaz:
https://doaj.org/article/d9f21499f61940fcb8e9ee4b21921d8d
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 19, Iss 1 (2018)
INTRODUCTION: The direct oral anticoagulants (DOACs) have demonstrated a more predictable effect and a more favorable risk-benefit ratio compared to the standard oral anticoagulant treatment for the prevention of stroke in patients with non-valvular
Externí odkaz:
https://doaj.org/article/c192edd904984a0195194481e85ebe60
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 15, Iss 1S, Pp 15-26 (2014)
OBJECTIVES: The aim of this study was to evaluate the cost‑effectiveness of apixaban in the prevention of thromboembolic events in patients with non‑valvular atrial fibrillation (NVAF) relatively to standard of care (warfarin or aspirin) from the
Externí odkaz:
https://doaj.org/article/fdec150737fd4e4f944c7890d2abaed2
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 15, Iss 4, Pp 101-112 (2014)
OBJECTIVES: The study evaluated the cost‑effectiveness of apixaban in preventing thromboembolic events in non‑valvular atrial fibrillation (NVAF) patients, as compared to other three available novel oral anticoagulant agents (NOACs), from the Ita
Externí odkaz:
https://doaj.org/article/0f725c03912d47c9a383d99568796100
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 15, Iss 1S, Pp 5-14 (2014)
OBJECTIVE: This study aims to perform a budget impact analysis of the use of three available novel oral anticoagulant agents (NOACs) for preventing thromboembolic events in Italian patients with non‑valvular atrial fibrillation (NVAF). METHODS: Est
Externí odkaz:
https://doaj.org/article/c8ba489119ea4616a68e2fce73a94a60
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 17, Iss 3 (2016)
BACKGROUND: Venous thromboembolism (VTE), a collective term for deep vein thrombosis (DVT) and pulmonary embolism (PE), is a serious vascular condition associated to high economic and clinical burden. Apixaban, a Novel Oral Anticoagulant (NOAC) has s
Externí odkaz:
https://doaj.org/article/b76590d1bd2e4447a75d06566bf0a214
Autor:
Marco Bellone, Pierluigi Sbarra
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 14, Iss 4, Pp 153-160 (2013)
BACKGROUND: Cardiovascular disease management and prevention represent the leading cost driver in Italian healthcare expenditure. In order to reach the target blood pressure, a large majority of patients require simultaneous administration of multipl
Externí odkaz:
https://doaj.org/article/7c3e2ebfe31849c79484681f22a4a401